$1.20
5.26% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US57055L1070
Symbol
MRKR

Marker Therapeutics, Inc. Stock price

$1.20
-0.25 17.24% 1M
-1.39 53.67% 6M
-1.91 61.41% YTD
-3.16 72.48% 1Y
-3.36 73.69% 3Y
-17.60 93.62% 5Y
-24.00 95.24% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.06 5.26%
ISIN
US57055L1070
Symbol
MRKR

Key metrics

Market capitalization $12.21m
Enterprise Value $-6.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.64
EV/Sales (TTM) EV/Sales -1.06
P/S ratio (TTM) P/S ratio 1.85
P/B ratio (TTM) P/B ratio 0.66
Revenue growth (TTM) Revenue growth -3.23%
Revenue (TTM) Revenue $6.59m
EBIT (operating result TTM) EBIT $-11.12m
Free Cash Flow (TTM) Free Cash Flow $-10.91m
Cash position $19.19m
EPS (TTM) EPS $-1.20
P/S forward 4.21
EV/Sales forward negative
Short interest 4.84%
Show more

Is Marker Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Marker Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Marker Therapeutics, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Marker Therapeutics, Inc. forecast:

Buy
100%

Financial data from Marker Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6.59 6.59
3% 3%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.24 4.24
15% 15%
64%
- Research and Development Expense 13 13
6% 6%
204%
-11 -11
17% 17%
-169%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
23% 23%
-169%
Net Profit -11 -11
37% 37%
-163%

In millions USD.

Don't miss a Thing! We will send you all news about Marker Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Marker Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons ...
Neutral
GlobeNewsWire
2 days ago
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses
Neutral
GlobeNewsWire
about one month ago
HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. W...
More Marker Therapeutics, Inc. News

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Head office United States
CEO Juan Vera
Employees 5
Founded 1991
Website www.markertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today